Alloy Wants Partners To Compete In Making Medicine, Not Technology Access

Alloy raises $75m in venture funding to further its mission of open-source antibody technology discovery. It also spins out portfolio companies, like ophthalmic-focused Broadwing.

Venture Capital Concept on the Mechanism of Metal Gears.
Alloy Therapeutics can expand its mission with a fresh infusion of $75m

Alloy Therapeutics, Inc. is taking an unusual route to drug discovery and development, as it works to make open-source antibody discovery technology and related services more widely available. The company, which unveiled a $75m series C financing on 2 April, operates with a philosophy that biopharmaceutical companies should compete to create the best medicines rather than vie over access to the best technologies.

Based in Boston, the privately held firm previously raised about $17.5m total in its series A and B financings, CEO...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.